Xcout Intel
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Subscribe to see SAB Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
SAB Biotherapeutics, Inc. at a glance
SAB Biotherapeutics, Inc. is a biotech company headquartered in Miami Beach, United States. It is publicly listed (SABS) with a market capitalisation of $343.9M. Xcout tracks 31 named people at SAB Biotherapeutics, Inc., including Samuel J. Reich (CEO & Director). Xcout recorded 1 job posting from SAB Biotherapeutics, Inc. in the last 90 days.
SAB Biotherapeutics, Inc. leadership
- Samuel J. ReichCEO & Director
- Christoph BauschExecutive Vice President & Chief Operating Officer
- Lucy ToExecutive Vice President & Chief Financial Officer
- Alexandra KropotovaExecutive Vice President & Chief Medical Officer
- Eddie Joe SullivanCo-Founder, President & Director
- Angie ParizekSenior Vice President of Clinical Operations
25 more named people on record for SAB Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
SAB Biotherapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $14M | 2 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at SAB Biotherapeutics, Inc.
Xcout recorded 1 job posting from SAB Biotherapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see SAB Biotherapeutics, Inc.'s hiring signals →
Investors
SAB Biotherapeutics, Inc. competitors
A few of SAB Biotherapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Polyneuron Pharmaceuticals is a venture-backed biotech and life sciences company headquartered in Basel, Switzerland. Founded in 2014, the company is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases.
Paulex Bio Inc. is a biotechnology company headquartered in San Diego, California, focused on transformative treatments for type 1 and type 2 diabetes. Its lead approach targets beta cell regeneration through an oral administration.
Cyxone AB is a clinical-stage biotechnology company headquartered in Malmö, Sweden. It focuses on developing a new generation of disease-modifying therapies for autoimmune and autoinflammatory diseases.
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
Zag Bio is a biotechnology research company headquartered in Cambridge, Massachusetts. The enterprise focuses on developing innovative therapies for autoimmune diseases by targeting the thymus gland to engage the body's natural T cell central tolerance mechanisms.
Get SAB Biotherapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on SAB Biotherapeutics, Inc. in Xcout Intel
- 31 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access